US Patent Issued to Vidac Pharma on Jan. 20 for "Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (HK2)-expressing cancers" (Israeli Inventors)

ALEXANDRIA, Va., Jan. 20 -- United States Patent no. 12,527,782, issued on Jan. 20, was assigned to Vidac Pharma Ltd. (Rehovot, Israel).

"Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (HK2)-expressing cancers" was invented by Vered Behar (Bet Zayit, Israel), Oren Menahem Becker (Mevasseret Zion, Israel), Hadas Tamar Pahima (Moshav Ahuzam, Israel) and Reut Yosef Hamo (Ramot Meir, Israel).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for treating, inhibiting, or s...